By Josée Rose
ALX Oncology is cutting about 30% of its workforce and realigning its focus.
The clinical-stage biotechnology company named Harish Shantharam as chief financial officer and Alan Sandler as chief medical officer.
ALX said its "strategic prioritization and resource optimization" plan, which primarily will affect its preclinical research department, is expected to extend its cash runway into the fourth quarter of 2026. As of Dec. 31, ALX had cash, cash equivalents and investments of $131.3 million.
The company expects results from several Phase 2 trials related to head and neck squamous cell carcinoma in the second quarter.
ALX said its loss for the three months ended Dec. 31 was 55 cents a share, compared with a loss of 93 cents in the year-earlier period, due to lower research and development expenses.
ALX also named Barbara Klencke and Chris Takimoto to its board of directors.
Write to Josée Rose at josee.rose@wsj.com
(END) Dow Jones Newswires
March 06, 2025 17:07 ET (22:07 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。